Additional drug combinations may carry a risk of more side effects though, raising concerns from some doctors. Regeneron ...

Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute, helped deliver positive news for the estimated 7 million Americans who take ...

Diabetes treatment with semaglutide was associated with significantly reduced risk for stroke compared with empagliflozin, ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Novo Nordisk A/S is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc. that had been touted ...